Results from the safety interim analysis of the Adjuvant chemoRadioTherapy In Stomach Tumors 2 (ARTIST 2) randomized, multi-center clinical trial.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e16029
Abstract: e16029Background: ARTIST 2 trial is being conducted to compare disease-free survival (DFS) in patients with D2-resected, node-positive, stage II or III gastric cancer (GC), treated with adjuvant ch... read more here.
Keywords: analysis adjuvant; trial; safety interim; interim analysis ... See more keywords
Safety and interim results from a phase II, single-arm study of atezolizumab and bevacizumab in Merkel cell carcinoma (MCC).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e21006
Abstract: e21006 Background: MCC is an aggressive neuroendocrine carcinoma of the skin. Avelumab (anti-PD-L1) was FDA approved for the treatment of metastatic MCC based on an overall response rate (ORR) of 32% in chemotherapy-refractory pts. In… read more here.
Keywords: carcinoma; safety interim; mcc; cell ... See more keywords